Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

82.26 +1.64 (+2.03%)
Streaming Delayed Price Updated: 3:41 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
2 Healthcare Stocks to Buy Hand Over Fist in January
Via The Motley Fool
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
From DexCom, Inc.
Via Business Wire
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market.
Smart rings are one of the hottest consumer electronics categories, as evidenced by exhibitors at CES 2025. Oura leads the market. 
Via Investor's Business Daily
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating. 
Via Chartmill
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Via The Motley Fool
Peering Into DexCom's Recent Short Interest
 
Via Benzinga
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
Via The Motley Fool
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Via The Motley Fool
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM
From Kahn Swick & Foti, LLC
Via Business Wire
Key Takeaways From DexCom Analyst Ratings
 
Via Benzinga
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
Via The Motley Fool
Exploring the Growth Potential of NASDAQ:DXCM as It Nears a Breakout.
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
Via Chartmill
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
Is DEXCOM INC (NASDAQ:DXCM) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
From DexCom, Inc.
Via Business Wire
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
2 Excellent Healthcare Stocks to Hold Through the Next Decade
Via The Motley Fool
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Via The Motley Fool
Analyst Expectations For DexCom's Future
 
Via Benzinga
These Analysts Revise Their Forecasts On DexCom Following Q3 Results
 
Via Benzinga
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest
Via The Motley Fool
Dexcom and ŌURA Announce Strategic Partnership
From DexCom, Inc.
Via Business Wire
Large-Cap Stocks In Trouble - Sunday, Nov. 17
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom
Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest Form 13F on Thursday and disclosed its trading activity from the prior quarter. 
Via Benzinga
Dexcom Helps People With Diabetes Take the First Step to Discover What They’re Made Of on World Diabetes Day
From DexCom, Inc.
Via Business Wire
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues
Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024. 
Via Investor's Business Daily
1 Stock to Buy Near Its 52-Week Low and Hold for 10 Years
This medical device company is down but not out. 
Via The Motley Fool
Why DexCom Stock Flopped on Friday
Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.